Trial Profile
Open Label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin (Prolonged-Release Melatonin) Mini Tablets in Children With Neurodevelopmental Disorders and Sleep Disturbances
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Melatonin (Primary)
- Indications Developmental disabilities; Neurodevelopmental disorders; Sleep disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors NEURIM Pharmaceuticals
- 03 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Jul 2013 New trial record